Ten years into its quest to validate a novel targeted drug delivery technology, Beijing-based Innolife is looking to bring a heart failure drug candidate into Phase III development to demonstrate the molecule’s ability to repair damaged cardiac tissue.
Key Takeaways
-
Innolife says INL1 (trientine hydrochloride) can help deliver trace element copper directly to damaged heart tissue to aid repair.
By combining trientine with trace elements in the tissue injury signalling system, Innolife hopes that its INL1 (trientine hydrochloride) can...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

